A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine

Diamond Headache Clinic

Status and phase

Completed

Phase 3

Conditions

Migraine

Treatments

Drug: Rizatriptan co-administered with Acetaminophen

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00300924

Merck 075-00

Merk 075-00

Details and patient eligibility

About

The purpose of this study is to test an experimental drug combination of two medications currently approved by the Food and Drug Administration (FDA) for migraine headache or other pain. These are called rizatriptan given with acetaminophen.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject is at least 18 years of age
Subject has at least a 6 month history of migraine, with or without aura
Subject can distinguish between migraine attacks and other types of headaches
Subject of childbearing potential agrees to use adequate contraception

Exclusion criteria

Subject typically has fewer than 1 or greater than 6 migraine attacks per month
Subject typically has greater than 10 headache days per month
Subject has evidence of ischemic heart disease
Subject has uncontrolled high blood pressure
Subject has a history, within 1 year, or current evidence of drug or alcohol abuse

*This list is not all inclusive*